About Us  |  BVA-100  |  Investor Relations  |  IDANT Division  |  Contact Us
 

About Us: Company

 
 

7/7/2010 - Daxor Announces that Rush University Medical Center of Chicago, IL Acquires BVA-100 Blood Volume Analyzer

  

5/27/2010 - Daxor Announces Publication of Review Article on Use of Blood Volume Analysis to Guide Ultrafiltration in the Management of Congestive Heart Failure

  

5/10/2010 - Daxor Corporation Announces First Quarter 2010 Earnings and Payment of a Dividend

  
 

______________________

 
     
  DAXOR Corporation Newsletter; Issue 1, March 2010  
  2009 Form 10-K  
  2009 Second Quarter Earnings  
  September 2009 10-Q  
  2009 Proxy Statement  
  2008 Annual Report  
 

DAXOR Corporation is a publicly traded company registered in the American Stock Exchange (DXR). We are an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient's blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility.

Our IDANT division provides (1) semen banking services, which include anonymous donor semen and semen storage, (2) autologous blood storage, (3) andrology services, which include semen analysis and sperm washing, and (4) general lab testing.

Ultimately the company's mission is to help hospitals and physicians incorporate DAXOR's advanced technologies to significantly improve the quality of patient care.


Menu Options

DAXOR Home Page

Mission Statement

Privacy Statement

Company Management

Careers

Contact Us

 

 

Corporate
Headquarters

350 Fifth Ave.
Suite 7120
New York, NY 10118
Phone: 212-330-8500
Fax: 212-244-0806


© 2010 DAXOR Corporation. All Rights Reserved.